| http://dbpedia.org/ontology/abstract
|
أولاراتوماب هو جسم مضاد وحيد النسيلة، طورت … أولاراتوماب هو جسم مضاد وحيد النسيلة، طورته شركة إمكلون ثم ليلي لعلاج الأورام الصلبة. في فبراير 2015، حصل على صفة دواء يتيم من وكالة الأدوية الأوروبية لعلاج . وفي أكتوبر 2016، أصدرت إدارة الغذاء والدواء الأمريكية تنويها بترخيص استعماله مع دوكسوروبيسين لعلاج أنواع معينة من ساركوما النسيج الرخو.لعلاج أنواع معينة من ساركوما النسيج الرخو.
, L’olaratumab (nom commercial : Lartruvo) est un anticorps monoclonal en cours d’évaluation pour le traitement de tumeurs solides. Il est dirigé contre le platelet-derived growth factor receptor alpha.
, Olaratumab, sold under the brand name Lart … Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").ical advantage (see below "Medical uses").
|
| http://dbpedia.org/ontology/alternativeName
|
Lartruvo
|
| http://dbpedia.org/ontology/casNumber
|
1024603-93-7
|
| http://dbpedia.org/ontology/drugbank
|
DB06043
|
| http://dbpedia.org/ontology/fdaUniiCode
|
TT6HN20MVF
|
| http://dbpedia.org/ontology/kegg
|
D09939
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/olaratumab +
|
| http://dbpedia.org/ontology/wikiPageID
|
26602636
|
| http://dbpedia.org/ontology/wikiPageLength
|
10071
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1063473347
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Cytochrome_P450 +
, http://dbpedia.org/resource/European_Union +
, http://dbpedia.org/resource/P-value +
, http://dbpedia.org/resource/Progression-free_survival +
, http://dbpedia.org/resource/Median +
, http://dbpedia.org/resource/Cancer_surgery +
, http://dbpedia.org/resource/Accelerated_approval_%28FDA%29 +
, http://dbpedia.org/resource/Doxorubicin +
, http://dbpedia.org/resource/FDA +
, http://dbpedia.org/resource/Eli_Lilly_and_Company +
, http://dbpedia.org/resource/Phase_I_clinical_trial +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Priority_review_%28FDA%29 +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Pharmacokinetic +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies_for_tumors +
, http://dbpedia.org/resource/Solid_tumor +
, http://dbpedia.org/resource/Transmembrane_pump +
, http://dbpedia.org/resource/Platelet-derived_growth_factor_receptor +
, http://dbpedia.org/resource/Volume_of_distribution +
, http://dbpedia.org/resource/Biological_half-life +
, http://dbpedia.org/resource/Intravenous_infusion +
, http://dbpedia.org/resource/Radiation_therapy +
, http://dbpedia.org/resource/Neutrophil +
, http://dbpedia.org/resource/European_Commission +
, http://dbpedia.org/resource/Hypersensitivity +
, http://dbpedia.org/resource/Randomised_controlled_trial +
, http://dbpedia.org/resource/Nausea +
, http://dbpedia.org/resource/Lymphopenia +
, http://dbpedia.org/resource/Category:Withdrawn_drugs +
, http://dbpedia.org/resource/Soft-tissue_sarcoma +
, http://dbpedia.org/resource/Tyrosine_kinase +
, http://dbpedia.org/resource/Breakthrough_therapy +
, http://dbpedia.org/resource/Proteolytic_enzyme +
, http://dbpedia.org/resource/Fast_track_%28FDA%29 +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/PDGFRA +
, http://dbpedia.org/resource/ImClone_Systems +
, http://dbpedia.org/resource/Category:Eli_Lilly_and_Company_brands +
, http://dbpedia.org/resource/Category:Breakthrough_therapy +
, http://dbpedia.org/resource/Statistical_significance +
, http://dbpedia.org/resource/Mucositis +
, http://dbpedia.org/resource/Platelet-derived_growth_factor_receptor_alpha +
, http://dbpedia.org/resource/Neutropenia +
, http://dbpedia.org/resource/Orphan_drug +
|
| http://dbpedia.org/property/atcPrefix
|
L01
|
| http://dbpedia.org/property/atcSuffix
|
FX10
|
| http://dbpedia.org/property/c
|
6554
|
| http://dbpedia.org/property/casNumber
|
1024603
|
| http://dbpedia.org/property/chemspiderid
|
None
|
| http://dbpedia.org/property/dailymedid
|
Lartruvo
|
| http://dbpedia.org/property/drugbank
|
DB06043
|
| http://dbpedia.org/property/eliminationHalfLife
|
950400.0
|
| http://dbpedia.org/property/h
|
10076
|
| http://dbpedia.org/property/kegg
|
D09939
|
| http://dbpedia.org/property/legalUk
|
POM
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/metabolism
|
Proteolytic enzymes
|
| http://dbpedia.org/property/n
|
1736
|
| http://dbpedia.org/property/o
|
2048
|
| http://dbpedia.org/property/proteinBound
|
None
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravenous_infusion +
|
| http://dbpedia.org/property/s
|
40
|
| http://dbpedia.org/property/source
|
u
|
| http://dbpedia.org/property/synonyms
|
IMC-3G3, LY-3012207
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/PDGFRA +
|
| http://dbpedia.org/property/tradename
|
Lartruvo
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
TT6HN20MVF
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
458283639
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Monoclonals_for_tumors +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Growth_factor_receptor_modulators +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Reflist +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Eli_Lilly_and_Company_brands +
, http://dbpedia.org/resource/Category:Withdrawn_drugs +
, http://dbpedia.org/resource/Category:Breakthrough_therapy +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies_for_tumors +
, http://dbpedia.org/resource/Category:Orphan_drugs +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Olaratumab?oldid=1063473347&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Olaratumab +
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.0bh8n1h +
, https://global.dbpedia.org/id/4ss8V +
, http://dbpedia.org/resource/Olaratumab +
, http://www.wikidata.org/entity/Q7083108 +
, http://ar.dbpedia.org/resource/%D8%A3%D9%88%D9%84%D8%A7%D8%B1%D8%A7%D8%AA%D9%88%D9%85%D8%A7%D8%A8 +
, http://fa.dbpedia.org/resource/%D8%A7%D9%88%D9%84%D8%A7%D8%B1%D8%A7%D8%AA%D9%88%D9%85%D8%A7%D8%A8 +
, http://fr.dbpedia.org/resource/Olaratumab +
, http://yago-knowledge.org/resource/Olaratumab +
|
| rdf:type |
http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/ontology/Drug +
|
| rdfs:comment |
Olaratumab, sold under the brand name Lart … Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").ical advantage (see below "Medical uses").
, L’olaratumab (nom commercial : Lartruvo) est un anticorps monoclonal en cours d’évaluation pour le traitement de tumeurs solides. Il est dirigé contre le platelet-derived growth factor receptor alpha.
, أولاراتوماب هو جسم مضاد وحيد النسيلة، طورت … أولاراتوماب هو جسم مضاد وحيد النسيلة، طورته شركة إمكلون ثم ليلي لعلاج الأورام الصلبة. في فبراير 2015، حصل على صفة دواء يتيم من وكالة الأدوية الأوروبية لعلاج . وفي أكتوبر 2016، أصدرت إدارة الغذاء والدواء الأمريكية تنويها بترخيص استعماله مع دوكسوروبيسين لعلاج أنواع معينة من ساركوما النسيج الرخو.لعلاج أنواع معينة من ساركوما النسيج الرخو.
|
| rdfs:label |
Olaratumab
, أولاراتوماب
|
